21-23 August 2017

Boston, MA, USA

 

Day One
Tuesday 22 August, 2017

Day Two
Wednesday 23 August 2017

Developing Preclinical In Vivo Models That are Predictive in the Clinic

08.30
Target Validation in Humanized Mouse Models of Pulmonary Fibrosis

Synopsis

• Overview of lung fibrosis models initiated by the adoptive transfer of human IPF cells in immunodeficient mice
• A key advantage of this model: human specific targeting in a preclinical setting
• A key disadvantage of this model: it is costly and takes several weeks to develop

08.50
From Translation to Clinical Outcomes: Effects of CTGF Blockade in a Mouse Radiation-Induced Lung Fibrosis Model

Synopsis

• Highlighting the role of CTGF as a central mediator of tissue remodelling and fibrosis
• Exploring the use of the mouse radiation-induced lung fibrosis model as a progressive, physiologically relevant model that is predictive of success in clinical trials
• Showcasing the therapeutic efficacy of pamrevlumab in rapidly altering the biology of the remodelled lung and in restoring normal lung structure and function

09.10
Session Q&A Panel

Synopsis

• Highlighting the role bleomycin induced models have played in advancing our understanding of IPF
• Addressing how as a community we can begin to supplement the model use with alternative systems
• Exploring regulatory concerns when developing IND packages for clinical development

09.30
Roundtable Sessions Followed by Moderator Feedback & Audience Debate

Synopsis

  1. Assessing The Potential of Combination Therapies in the Treatment of IPF
  2. Applying Machine Learning to HRCT
  3. Developing Targeted Therapeutics for IPF

10.30
Morning Refreshments & Networking

Advancing the Clinical Translation of IPF Therapeutics Through Non Invasive Technologies

11.30
Quantitative Imaging Techniques Aiding Subclinical Diagnoses and Offering Translational Lessons for In Vivo Models

  • Jonathan Goldin Professor of Radiology, Medicine and Bio-Physics Executive Vice Chairman, Department of Radiological Sciences, UCLA

Synopsis

• Exploring CT criteria for the classification of IPF
• Highlighting novel applications for CT in enriching study populations
• Describing a role for QIA as a potential outcome measure in treatment trials

11.50
Predicting Outcomes in IPF Using Computer-Based CT Analysis

Synopsis

• Divulging the basic mechanisms behind CT quantitation in IPF
• Highlighting the vascular changes in the lung identified in IPF patients through CT based imaging
• Reviewing concepts linking vascular enlargement in IPF and mortality

12.10
Functional Respiratory Imaging in Idiopathic Pulmonary Fibrosis

Synopsis

  • Moving from Lung Function to overall Lung Health
  • Regional pathophysiological lung changes in IPF
  • Regional lung parameters that describe the IPF disease and reveal key insights

12.30
Session Q&A Panel

  • Jonathan Goldin Professor of Radiology, Medicine and Bio-Physics Executive Vice Chairman, Department of Radiological Sciences, UCLA
  • Joseph Jacob Research Collaborator, Mayo Clinic Rochester
  • Jan De Backer CEO, FLUIDDA INC

Synopsis

• Answering how machine learning can be applied to high resolution CT to aid in the prediction of IPF in preclinical systems
• Discussing how imaging based biomarker-guided trial design can be utilized to aid in the execution of more efficient proof-of-concept studies
• Examining the complex relationship between pathology and imaging in lung fibrosis and how these advances can be applied to translational research

13.00
Lunch & Networking

Novel Therapeutic Approaches to the Treatment of IPF

14.00
i-Bodies: A Novel Therapeutic Approach For IPF

  • Sam Cobb Chief Executive Officer, AdAlta

Synopsis

• Highlighting the critical role the chemokine receptor, CXCR4, has shown in the development of Idiopathic Pulmonary Fibrosis
• Revealing AdAlta’s unique human single domain protein platform to identify a novel i-body, AD-114, that specifically antagonizes CXCR4 and shows both anti-inflammatory and anti-fibrotic effects in a bleomycin induced model of IPF. It only targets diseased IPF human tissue, with no effects on normal lung tissue or any evidence of off target effects
• Demonstrating the anti-fibrotic properties of AD-114 in multiple animal and in vitro models of fibrosis, suggesting that it may have broad applications in fibrosis of organs other than the lung

14.20
Pentraxin-2 Therapeutics; Targeting Monocyte & Macrophage Differentiation

  • Rick Jack President & Chief Scientific Officer, Promedior Inc.

Synopsis

• Importance of in vitro and ex vivo assays to determine PRM-151’s MOA and links to the in vivo observations
• Utility of in vivo models in identifying potential therapeutic activity of PRM-151 (recombinant human pentraxin-2)
• Translating PRM-151 into the clinic: how nonclinical data can guide IPF clinical trials

14.40
Role of inhaled Nitric Oxide in the Treatment of Pulmonary Fibrosis

Synopsis

  • Understand the dual action of inhaled nitric oxide in the treatment of pulmonary diseases
  • Understand the available clinical data on the use of chronic inhaled nitric oxide in the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with pulmonary fibrosis
  • Understand the clinical trial design of an upcoming clinical trial of the use of chronic inhaled nitric oxide in the treatment of pulmonary fibrosis

15.00
Session Q&A Panel

  • Sam Cobb Chief Executive Officer, AdAlta
  • Rick Jack President & Chief Scientific Officer, Promedior Inc.

Synopsis

• Highlighting the therapeutic insights for IPF from the small molecule toolbox
• Evaluating the new implications for drug therapies from the novel insights into the pathogenesis of IPF
• Highlighting the critical importance and potential benefit of new and alternative treatment modalities to small molecules

15.30
Afternoon Refreshments

Clinical Insights for Idiopathic Pulmonary Fibrosis in Drug Development

16.00
Tralokinumab in IPF:  Results of a phase 2 trial

  • Gene Colice, Medical Director & Global Clinical Lead for Tralokinumab, AstraZeneca

Synopsis

  • Review the scientific rationale for using tralokinumab to treat IPF
  • Describe the efficacy outcomes used to assess tralokinumab treatment effect
  • Discuss the results of the phase 2 trial

16.20
Development of JNK Inhibitors for the Treatment of IPF

Synopsis

• Highlighting the role of C-Jun N-terminal kinase (JNK) as a key mediator in the pulmonary fibrotic process
• Evaluating the preclinical efficacy of the JNK inhibitors, CC-930 & CC-90001, in preclinical fibrosis models and in a phase I/II trial in IPF patients
• Demonstrating the ability of CC-930 inhibition of JNK enzymatic activity in modulating systemic markers in IPF patients, including MMP-7, tenascin C and SP-D plasma protein levels
• CC-930 JNK inhibition supports the use of these biomarkers for tracking disease progression and the potential clinical benefit of this novel intervention in IPF

16.30
Session Q&A Panel

  • Gene Colice, Medical Director & Global Clinical Lead for Tralokinumab, AstraZeneca
  • Gerald Horan Principal Investigator, Celgene Corporation
  • Deborah A. Quinn Chief Medical Officer, Bellerophon Therapeutics

Synopsis

• Defining more meaningful, industry wide preclinical endpoints
• Exploring the evolved regulatory path for IPF, from preclinical to early clinical development

16.50
Close of Conference Day 2